Introduction
The Ink4a/Arf locus encodes two proteins, p16
INK4a and p14 ARF (p19 ARF in the mouse), in overlapping reading frames which are commonly codeleted in a large variety of human cancers (reviewed in Lowe and Sherr 2003) . Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002) . Likewise, mice lacking both p16
INK4a and p19 ARF (Ink4a/ArfÀ/À), lacking p16
INK4a only (p16 INK4a À/À), or p19 ARF only (p19 ARF À/À) are prone to tumors spontaneously and are sensitive to carcinogens, albeit with apparent differences in latency and tumor spectra (Serrano et al., 1996; Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a) . From these data, it appears that the unusual genomic structure of Ink4a/Arf allows for concomitant inactivation of two archetypal tumor-suppressor pathways, Rb and p53, through deletion of this single locus.
While both proteins play a role in culture-induced growth arrest, the relative roles of each vary in a celltype-and species-specific manner. For example, under certain conditions, p16
INK4a accumulates in serially passaged primary human cells, and immortalization of these cells requires p16
INK4a loss, generally through promoter methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998; Kiyono et al., 1998; Rheinwald et al., 2002; Sviderskaya et al., 2003) . On the other hand, no clear role for p14 ARF in the growth arrest of cultured human cells has been consistently demonstrated (Munro et al., 1999; Wei et al., 2001; Rheinwald et al., 2002) . In murine cells, p16
INK4a appears to participate in culture-induced arrest of a few cell types (e.g. astrocytes (Bachoo et al., 2002) , macrophages (Randle et al., 2001) , and v-abl transduced lymphocytes (Sachs et al., in submission)), but p19 ARF appears more important in most of these cases. In MEFs, for example, p19 ARF loss is sufficient for immortalization, while loss of p16
INK4a is not (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a) . Likewise, RAS-induced growth arrest requires p16 INK4a -Rb in human cells (and not ARF), while the opposite appears true in MEFs (Kamijo et al., 1997; Serrano et al., 1997; Zhu et al., 1998; Krimpenfort et al., 2001; Sharpless et al., 2001a; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002) . These cell-type and species discrepancies are presently unexplained. It appears, however, that a somewhat generic feature(s) of cell culture ('oncogenic stress') is capable of inducing both p16
INK4a and ARF expression in a multitude of cell types (Sherr and DePinho, 2000) . It is not known, however, if the characteristics of a nascent tumor that induce p16
INK4a and ARF expression are related to those stimuli that induce the Ink4a/Arf locus in culture.
Despite a number of previous studies of isolated or combined p16
INK4a and p19 ARF deficiency (Serrano et al., 1996; Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a; reviewed in Sherr (2001) , comparison of these series is difficult because of differences in genetic background, allele design, housing environment, pathologic characterization, etc. Here, we report the comparison of these mice and derivative cells to those lacking p16
INK4a only (p16 INK4a À/À), both p16
INK4a and p19 ARF (Ink4a/ArfÀ/À), and p53 (p53À/ À), all in a similar genetic background, and followed and analysed in common facilities by a single group of investigators over the same period.
Results

Mice lacking p19
ARF were generated using standard gene-targeting techniques, with Cre-mediated excision of the neomycin selection cassette ( Figure 1a ) in a manner similar to p16
INK4a
À/À mice (Sharpless et al., 2001a) . Homologous integration and correct Cremediated excision were determined by Southern analysis (Figure 1b ) and PCR (Figure 1c ), respectively. This targeting strategy generated a premature stop codon in exon 1b, leaving the cis-regulatory elements of p19 ARF and p16
INK4a unperturbed. Fibroblasts from p19 ARF À/À embryos demonstrated loss of p19 ARF by Western blotting using a C-terminal antibody (Figure 1d ), and neither p53 nor its downstream target p21 were stabilized by serial passage in these cells consistent with their functional deficiency of p19 ARF (Figure 1d and e). In contrast to a previously described p19 ARF -specific KO which retains the neomycin selection cassette at the locus (Kamijo et al., 1997) , MEFs from these animals demonstrated normal p16 INK4a expression at early passage (Figure 1d ), although p16
INK4a expression was greater at later passages (e.g. P9 in Figure 1d) , expression . These data confirm that p19 ARF is the dominant effector of MEF 'senescence' in response to serial passage or oncogenic RAS overexpression. In contrast, p16
INK4a only modestly contributes to the growth characteristics of MEFs, and then only when highly expressed (e.g. after prolonged periods in culture) or in the setting of attenuated p19
ARF expression (e.g. after prolonged culture at confluence).
To assess the effects of p19 ARF loss in vivo, we generated cohorts by intercrossing p19 ARF þ /À animals lacking the Cre-deletor transgene, and monitored these mice for the analysis of spontaneous and DMBAinduced tumor incidence. As previously reported (Kamijo et al., 1997 (Kamijo et al., , 1999 , p19 ARF À/À animals were significantly more tumor prone than p19 ARF þ / þ littermates (Po0.001 for both spontaneous and carcinogen-induced tumors, Figure 3a INK4a expression . These data confirm that p19 ARF is a bona fide tumor suppressor, but also strongly suggest that the Ink4a/Arf locus encodes additional tumor-suppressor activity represented by p16
INK4a . The tumor spectrum of p19 ARF À/À animals was more similar to p53À/À than p16 INK4a À/À or Ink4a/ArfÀ/À mice in a comparable genetic background (Table 1) . The most common tumor in p19 ARF À/À mice was a lymphocytic lymphoma of the thymus and/or lymph nodes. Animals lacking p19 ARF also developed an increased incidence of spindle cell neoplasms (most likely soft tissue sarcomas, see Sharpless et al., 2001a Sharpless et al., , 2002 , and carcinomas, particularly of the lung. The latter is of particular interest as spontaneous epithelial p16INK4a and p19ARF in murine cancer NE Sharpless et al tumors are not frequently detected in Ink4a/ArfÀ/À, p53À/À or p16
INK4a À/À mice. While FVB mice are predisposed to lung tumors (Festing, 1998) , a similar increase in carcinoma has also been observed in mice lacking p19 ARF in a different genetic background (B6/ 129) (Kamijo et al., 1997 (Kamijo et al., , 1999 . Although a few mice demonstrated neurologic phenotypes (e.g. hind-limb paralysis, seizures), 1 mm sectioning of the brain of these animals did not reveal any glial tumors (n ¼ 12, p19 ARF þ /À or À/À mice examined). Three of the six mice with hind-limb paralysis demonstrated osteosarcoma of the spine, and one animal with circling behavior exhibited a nonmalignant cerebral arteriovenous malformation with hemorrhage. In contrast, mice lacking Ink4a/ArfÀ/À predominantly develop a widely disseminated histiocytic tumor involving the spleen, peripancreatic and other lymph nodes or other sites ('histiocytic lymphoma'). This tumor is the most common type seen in mice on the FVB background (485% of tumors in two large cohorts; Sharpless et al., 2001b; Artandi et al., 2002) . It also occurs, albeit with less frequency, in p16
INK4a À/À mice, but not in p19 ARF À/À mice (Table 1) . In aggregate, these data imply that p19
ARF is an important tumor suppressor in a variety of tissues of mesenchymal, lymphoid, and epithelial origin.
Single-dose treatment with the potent carcinogen DMBA, on the other hand, produced similar tumor spectra in wild-type, p16
INK4a À/À, and p19 ARF À/À mice. Animals of all three backgrounds demonstrated predominantly lymphoma, spindle cell tumors, and lung tumors (Table 1) , although the latency was much shorter in p16
INK4a À/À or p19 ARF À/À animals ( Figure 3b ). While mice lacking p16
INK4a À/À developed proportionally fewer lymphocytic lymphomas than either wild-type or p19 ARF À/À animals, they instead demonstrated an increased incidence of spindle cell neoplasms after DMBA, a tumor type to which they are also more prone to develop spontaneously. The only tumor type that was unique to a particular genotype after DMBA exposure was the finding of a low frequency of melanoma in p16
INK4a À/À animals, as has been previously reported (Krimpenfort et al., 2001; Sharpless et al., 2001a) . Intriguingly, while p19 ARF À/À lung tumors 
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Ink4a/ArfÀ/À Not determined, comparable colony followed by Serrano et al. (1996) As cohorts were not followed for equal lengths of time, the tumor incidences are shown as the percentage of the total number of tumors analysed. The total number of tumors per genotype is indicated p16INK4a and p19ARF in murine cancer NE Sharpless et al were larger (7.8 versus 28.7 mm 2 , P ¼ 0.04) and more likely to cause morbidity (e.g. tachypnea, hemothorax) than in wild-type littermate animals; the number of tumor nodules seen in p19 ARF À/À was not significantly increased, in contrast to p16
INK4a À/À mice (Sharpless et al., 2001a) . These data are most consistent with the notion that both p16
INK4a and p19 ARF inhibit DMBAinduced tumors in largely the same cell types, but with distinct mechanisms of action.
Discussion
We have described the generation of a novel p19 ARF specific knockout strain and its comparison to p16 INK4a , Ink4a/Arf, and p53 deficient animals. The phenotypes of these p19 ARF À/À mice and cells are similar to those observed in a previously described p19 ARF knockout from the Sherr lab (p19 ARF CS) (Kamijo et al., 1997 (Kamijo et al., , 1999 . Cells from this p19 ARF À/À strain, however, demonstrate normal p16
INK4a expression at early passage compared to littermate p19 ARF þ / þ animals, while cells from the previously described strain demonstrate a several-fold increase in p16
INK4a expression (Kamijo et al., 1997; Lin and Lowe, 2001) . This difference likely stems from the targeting strategy, as the p19 ARF CS mice were generated with a remnant neomycin selection that presumably disrupts the p19 ARF promoter. This result supports the view that p16
INK4a expression is reduced, at least in some circumstances, through promoter competition with p19 ARF , as has previously been suggested (Mao et al., 1995; Stone et al., 1995) .
Also, the strains differ somewhat in their tumor latency. Several groups (Kamijo et al., 1997 (Kamijo et al., , 1999 Eischen et al., 2002; Tolbert et al., 2002) have reported following cohorts of the p19 ARF CS mice for spontaneous tumors; all report median tumor latencies in the 27-49 week range, whereas the strain reported in this series appears to develop tumors B10-30 weeks later. A possible explanation is that this targeting strategy generates a hypomorphic allele as a transcript encoding the first 11 amino acids of p19 ARF is produced. Even in the unlikely event that this transcript is translated, however, previous results suggest that such a small fragment of p19 ARF could not bind mdm2, could not stabilize p53, and would not cause growth arrest in cells (Pomerantz et al., 1998; Weber et al., 2000; Korgaonkar et al., 2002) . Along these lines, MEFs from this p19 ARF knockout strain do not exhibit evidence of intact p19 ARF function in vitro (Figures 1d, e and 2a-c) . Another possible explanation for these differences is that the increased expression of p16
INK4a seen in the p19 ARF CS knockout could contribute to the differences in phenotype. While it seems paradoxical that the strain with increased p16
INK4a expression in vitro also demonstrates increased tumorigenesis in vivo, it is possible that developmental p16
INK4a overexpression might select for compensatory epigenetic events that attenuate the Rb pathway function. Finally, these differences between the p19 ARF -deficient strains could result from differences in environment or genetic background (e.g. FVB versus C57Bl/6).
In accordance with the Sherr group (Kamijo et al., 1997) , we have demonstrated that most of the in vitro phenotypes identified in Ink4a/ArfÀ/À MEFs are the result of p19 ARF deficiency. That is, transformation by cMyc and H-Ras, improved growth at low density, and enhanced growth by 3T9 assay are all seen in p19 ARF À/À MEFs, to an extent comparable to that seen in Ink4a/ ArfÀ/À cells. Therefore, p16
INK4a only seems to become an important determinant of MEF growth when highly expressed (e.g. at late passage when p16
INK4a loss facilitates immortalization (Sharpless et al., 2001a) ), or in the setting of reduced p19 ARF expression (e.g. growth at high density ). In contrast to MEFs, however, p16
INK4a has been noted to be a more significant determinant of the in vitro growth of murine lymphocytes, macrophages, and astrocytes (summarized in Table 2 ; Randle et al., 2001; Sharpless et al., 2001a; Bachoo et al., 2002; and Sachs et al., in submission) . Furthermore, there are extensive data to suggest that p16
INK4a plays a more important role in regulating the growth of a variety of human cell types (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998;  Kiyono et al., 1998; Zhu et al., 1998) , whereas the role of p14 ARF in these settings is unclear (Munro et al., 1999; Wei et al., 2001; Rheinwald et al., 2002) . Therefore, the modest importance of p16
INK4a as a determinant of MEF growth appears unusual among primary cell cultures from both human and mouse. A likely explanation for this observation is that even at early passage, MEFs highly express the other INK4-class regulators p18
INK4c and p19
INK4d . Therefore, p16
INK4a may be a stoichiometrically less important regulator of cdk4/6 activity than these other INK4 proteins in earlypassage MEFs. A compilation of results obtained from p16 INK4a À/À, p19 ARF À/À, Ink4a/ArfÀ/À, p53À/À, and p16
INK4a /p53 compound null mice and cells is shown in Table 2 (present data; (Sharpless et al., 2001a (Sharpless et al., , b, 2002 Bachoo et al., 2002; Kannan et al., 2003) . All of these experiments were performed on mice in a comparable genetic background (42 backcrosses to FVB), housed in a common facility, and followed by a single group of observers over a 4-year period. These cellular and organismal data unequivocally demonstrate genetic cooperation between p16
INK4a and p19 ARF loss, as well as between p16
INK4a and p53 loss. In summary, the issue of which protein encoded by the Ink4a/Arf locus encodes tumor-suppressor activity appears definitively resolved by the collective experimental evidence of this report and others (Kamijo et al., 1997 (Kamijo et al., , 1999 Krimpenfort et al., 2001; Sharpless et al., 2001a Sharpless et al., , 2002 Sharpless et al., , 2003 Bachoo et al., 2002; Kannan et al., 2003) . Clearly, p16
INK4a and p19 ARF participate in distinct antitumor pathways, and there is ample evidence from human and mouse studies for cooperation between the combined loss of both proteins. These results bring into sharp relief, however, the limitations of resistance to culture-induced growth arrest, a phenotype depending on p19 ARF in MEFs and p16
INK4a
in most cultured human cells, as a widely utilized surrogate of cancer-relevant activity. A more likely explanation for the intimate but inconsistent relationship between in vitro immortalization and tumorigenesis is that the act of culture and the early stages of tumor formation share common features. That is, nascent tumors in vivo likely receive Ink4a/Arf-dependent growth-inhibitory signals in response to aberrant or inappropriate proliferation that are similar to the culture-related stimuli that induce p16 INK4a and p19 ARF in vitro.
Methods
Targeting of p19 arf
Approximately 17 kb of genomic sequence containing exons 1 and 2 of p15 INK4b and exon 1b of p19 ARF was subcloned and mapped ( Figure 1a) . A floxed PGK-neomycin cassette was cloned into a BssHII site within exon 1b of a 4.4 kb EcoR1-Acc fragment (Figure 1a) , and then a targeting construct generated by three-part ligation of the long arm, the EcoR1 fragment with Neo cassette, and pKS containing TK for negative selection. The structure of the targeting vector was confirmed, and it was then electroporated into TC1 cells. Correct targeting was confirmed by Southern blotting (Figure 1b) and PCR (not shown). For Southern analysis, a 250 bp ApaL1-EcoR1 fragment that was external to the targeting vector was used. Blastocyst injections were performed using homologously targeted ES cells. High-percentage chimeras were then crossed to a Cre-deletor strain (EIIa-CRE; Lakso et al., 1996) to remove the selection cassette, and correct excision was confirmed by Southern (not shown), PCR ( Figure 1c ) and direct sequencing of the targeted allele. PCR was performed using primers that flank the remnant LoxP site: p193L (5 0 -GTC GCA GGT TCT TGG TCA CT-3 0 ) and p194R (5 0 -ATG TTC ACG AAA GCC AGA GC-3 0 ). A transcript is weakly expressed from the engineered exon 1b that encodes the first 11 amino acids of p19 ARF , and then a premature stop codon (not shown).
Mouse colony, histopathology, and cell culture After Cre-mediated excision of the selection cassette, animals were backcrossed to WT FVB females to remove the Cre transgene. N2 and N3 FVB colonies were then generated by backcrossing p19 ARF þ /À animals. Littermate tumor cohorts were monitored a minimum of 3 Â per week. Ink4a/Arf, p16
INK4a
, p53, and p16
/p53 cohorts were generated by similar mating schemes of heterozygous intercrosses of animals after backcrossing two to four generations to FVB/n (Taconic). All animals were housed in a common facility, followed by a common group of investigators, and histopathologically analysed in a common way. Data from the p16
À/À and Ink4a/ArfÀ/À cohorts have been previously published (Sharpless et al., 2001b , although the Kaplan-Meier and tumor spectrum analyses from the p16
IN-
K4a
À/À cohort were updated for this work (Figure 2a-c) . Histopathological analysis and tumor classification were performed as described (Sharpless et al., 2001b . In three animals killed for neurological symptoms (of 41 p19 ARF À/À in the cohort), the cause of death could not be determined, but they are included in the estimate of median tumor-free survival by Kaplan-Meier analysis (Figure 2a) , although it is improbable that these deaths were secondary to cancer. MEFs from all strains were made in an identical manner from day 13.5 embryos of heterozygous intercrosses, as previously described (Sharpless et al., 2001a) . Cell culture, in vitro assays, flow cytometry, and Western blotting were performed as previously described (Sharpless et al., 2001a) . For Western blotting, the following antibodies were used: p16
INK4a (M156, Santa Cruz), p19 ARF (Ab80, Novus), p21 (F-5, Santa Cruz), actin (C-11, Santa Cruz) and p53 (CM5, Novocastra). Immunohistochemistry was done as described previously (Rheinwald et al., 2002) with some modifications. Briefly, cells were BRDU pulsed for 24 h and fixed in 4% paraformaldehyde at indicated passages, incubated in 0.1% Triton X-100, then treated for 1 h with 0.2 N HCl, and neutralized with 0.1 M sodium borate buffer. Cells were stained using antibodies to BrdU (Roche) and p19 ARF (Ab80, Novus) for 1 h. Proteins were visualized by using AlexaFluor562 and 488 Molecular Probes secondary antibodies. For cell counting, 4600 cells per genotype were counted from three matched pairs of independent littermate cultures at passage 5-11 and compared with a two-sided Fisher's exact test. DMBA treatment was performed as described (Serrano et al., 1996) . Almost all animals killed at 415 weeks after DMBA treatment demonstrated pulmonary adenomas, but these tumors were only included in the KaplanMeier analysis and tumor spectra (Figure 2b and Table 1) when they contributed to the cause of death (for details, see Sharpless et al., 2001a) . p16INK4a and p19ARF in murine cancer NE Sharpless et al
